---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-003715"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:55:33.911692+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q1 net loss $1.8M; PH-762 shows 4 complete responses in Phase 1b trial

## Summary
- Cash $13.3M at March 31 vs $5.4M Dec 31; raised $9.2M from offerings and $2.9M from warrant exercises.
- Net loss $1.8M for Q1 2025 vs $2.2M in Q1 2024; R&D expenses down 23% to $0.886M.
- Phase 1b PH-762: 4 of 9 cSCC patients had pathologic complete response; no dose-limiting toxicities.
- 4th cohort enrolling; company expects to complete enrollment in Q3 2025.
- Sufficient capital to complete treatment phase of Phase 1b trial.

## SEC filing metadata
- accession: 0001683168-25-003715
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/0001683168-25-003715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-003715
- JSON: https://secwatch.observer/filing/0001683168-25-003715.json
- Plain text: https://secwatch.observer/filing/0001683168-25-003715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.